Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount raised topping $331 million. The two-year-old South San Francisco-based ...
Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the ...
Septerna, Inc. (NASDAQ:SEPN) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts greatly increased ...
Septerna has secured $150 million in a series B fundraise, money that will go toward two newly unveiled programs including moving its first G-protein-coupled receptor (GPCR) drug into the clinic. The ...
Septerna, Inc. ( NASDAQ:SEPN ) defied analyst predictions to release its first-quarter results, which were ahead ...
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial ...
Analysts' ratings for Septerna (NASDAQ:SEPN) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how ...
Septerna reported $137.5 million in cash and securities as of September 2024, with additional funds from its IPO expected to support operations into the second half of 2027. The company is also ...
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for ...
Septerna Inc. (NASDAQ:SEPN) and Novo Nordisk A/S (NYSE:NVO) announced an exclusive global collaboration and license agreement on Wednesday. The pact covers discovering, developing, and commercializing ...
For scientists developing new drugs, it’s hard to go wrong targeting a family of receptors that regulate virtually every known process in human beings. G protein-coupled receptors (GPCRs) are found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results